References
- Hargreave FE, Nair P. The definition and diagnosis of asthma. Clin Exp Allergy. 2009;39(11):1652–1658. doi:10.1111/j.1365-2222.2009.03321.x.
- D’Silva L, Hassan N, Wang HY, et al. Heterogeneity of bronchitis in airway diseases in tertiary care clinical practice. Can Respir J. 2011;18(3):144–148. doi:10.1155/2011/430317.
- Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716–725. doi:10.1038/nm.2678.
- Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013.
- Woolnough K, Wardlaw AJ. Eosinophilia in Pulmonary Disorders. Immunol Allergy Clin North Am. 2015;35(3):477–492. doi:10.1016/j.iac.2015.05.002.
- Curtis C, Ogbogu PU. Evaluation and Differential Diagnosis of Persistent Marked Eosinophilia. Immunol Allergy Clin North Am. 2015;35(3):387–402. doi:10.1016/j.iac.2015.04.001.
- Pereira CAC, Ferro FM, Matos A, Antunes M, Cusati P. Angiolymphoid hyperplasia with eosinophilia in the lungs: a complex name for an innocuous disease?J Bras Pneumol. 2020;46(3):e20190365. doi:10.36416/1806-3756/e20190365.
- Moran CA, Suster S. Angiolymphoid hyperplasia with eosinophilia (epithelioid hemangioma) of the lung: a clinicopathologic and immunohistochemical study of two cases. Am J Clin Pathol. 2005;123(5):762–765. doi:10.1309/UN1AQ2WJU9HDD72F
- Ribeiro L, Souto M, Loureiro A. Angiolymphoid Hyperplasia With Eosinophilia of the Lung. Arch Bronconeumol (Engl Ed)). 2018;54(6):340–342. doi:10.1016/j.arbres.2017.12.013.
- Onishi Y, Ohara K. Angiolymphoid hyperplasia with eosinophilia associated with arteriovenous malformation: a clinicopathological correlation with angiography and serial estimation of serum levels of renin, eosinophil cationic protein and interleukin 5. Br J Dermatol. 1999;140(6):1153–1156. doi:10.1046/j.1365-2133.1999.02880.x.
- Braun-Falco M, Fischer S, Plötz SG, Ring J. Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab). Br J Dermatol. 2004;151(5):1103–1104. doi:10.1111/j.1365-2133.2004.06239.x.